WO2026012411 - EXATECAN DERIVATIVE AND USE THEREOF
National phase entry is expected:
Publication Number
WO/2026/012411
Publication Date
15.01.2026
International Application No.
PCT/CN2025/107799
International Filing Date
10.07.2025
Title **
[English]
EXATECAN DERIVATIVE AND USE THEREOF
[French]
DÉRIVÉ D'EXATÉCAN ET SON UTILISATION
[Chinese]
依喜替康衍生物及其用途
Applicants **
SHANGHAI HUAOTA BIOPHARMACEUTICAL CO., LTD.
HUABO BIOPHARM (SHANGHAI) CO., LTD.
Inventors
ZHENG, Changping
XU, Jingen
PENG, Guoyuan
ZHAN, Yifan
ZHU, Xiangyang
Priority Data
202410935181.0
11.07.2024
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
CNIPA
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 1697 | |
| EPO | Filing, Examination, Granting | 11880 | |
| Japan | Filing, Examination, Granting | 2030 | |
| South Korea | Filing, Examination, Granting | 1867 | |
| USA | Filing, Examination, Granting | 4740 |
Total:
22,214
Contact Us
Abstract[English]
The present application relates to an exatecan derivative having a structure as represented by formula (I), or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof. The present application further relates to an ADC of the exatecan derivative, a pharmaceutical composition, a preparation method therefor and the use thereof.[French]
La présente demande concerne un dérivé d'exatécan ayant une structure telle que représentée par la formule (I), ou un stéréoisomère de celui-ci, ou un sel pharmaceutiquement acceptable de celui-ci. La présente demande concerne en outre un ADC du dérivé d'exatécan, une composition pharmaceutique, un procédé de préparation correspondant et une utilisation associée.[Chinese]
本申请涉及一种依喜替康衍生物，具有式(I)所示的结构，或其立体异构体、或其药学上可接受的盐。本申请还涉及所述依喜替康衍生物的ADC、药物组合物、制备方法以及用途。